Ontario Institute for Regenerative Medicine

OIRM operates as a translational network rather than a reactive grant-maker. It assembles disease-specific teams — each spanning academic investigators, clinicians, and industry partners — and funds them against milestones tied to clinical adoption. The model originated with Ontario's 2011 health-research strategy and means the institute actively manages project portfolios rather than simply disbursing and monitoring.

The institute's main disease-team programs cover cardiac regeneration, neural repair and neurodegeneration, diabetes — with an emphasis on cell-replacement strategies — musculoskeletal disorders, and ocular disease. Project selection reflects Ontario's population disease burden and the province's existing academic strengths in stem-cell biology.

OIRM does not hold equity positions. Commercialization and intellectual-property management are handled by partner organizations, primarily the Centre for Commercialization of Regenerative Medicine (CCRM). OIRM's funding creates the translational data that de-risks those assets for CCRM, which then structures spinout vehicles and licenses.

Disease-team investigators are drawn from the University Health Network, the Ottawa Hospital Research Institute, McMaster University, the University of Toronto, and several other Ontario research hospitals. Industry matching often comes through CCRM's consortium, which includes large-cap biopharma and cell-therapy manufacturing firms.

The institute launched with a commitment from the Government of Ontario's Ministry of Colleges and Universities, supplemented by federal tri-council grants and industry matching. Funding is renewed on a multi-year cycle tied to Ontario's research-innovation budgets; the most recent disease-team cycle was announced in 2023. Exact dollar figures are not published as a consolidated endowment or fund size.